Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)
NCT ID: NCT04558450
Last Updated: 2021-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
360 participants
INTERVENTIONAL
2020-09-21
2033-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit
carotid-femoral pulse-wave velocity
early vascular aging tests
Group 2
Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit
carotid-femoral pulse-wave velocity
early vascular aging tests
Group 3
Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization
carotid-femoral pulse-wave velocity
early vascular aging tests
Group 4
4\) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative
carotid-femoral pulse-wave velocity
early vascular aging tests
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carotid-femoral pulse-wave velocity
early vascular aging tests
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* written informed consent;
* affiliation to a social security regime;
* a recent diagnosis of COVID19 (6±3 months) proven by PCR or serology (for group 1,2,3)
* hospitalization in intensive care unit for COVID19 (for group 1)
* hospitalization in a medicine unit for COVID19 (for group 2)
* no hospitalization for COVID19 or hospitalization less than 24h (for group 3)
* a negative test for SARS-nCOV2 infection (PCR or serology)(for group 4)
Exclusion Criteria
* Inability to express consent of the study
* Diseases carrying out a life -expectancy \<1 year according to clinical judgment
* Pregnancy and breastfeeding
* Foreseen inability to attend scheduled visits
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Association for Research into Arterial Structure and Physiology
UNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre BOUTOUYRIE, MD PHD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU Nancy
Nancy, , France
Hôpital Européen Georges Pompidou - APHP
Paris, , France
CHU Rouen
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Athanase BENETOS, PhD
Role: primary
Pierre BOUTOUYRIE, PUPH
Role: primary
Jérémy BELLIEN, PUPH
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
general description of the study
summary and presentation of the global CARTESIAN initiative
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP200762
Identifier Type: OTHER
Identifier Source: secondary_id
20.07.24.57438
Identifier Type: OTHER
Identifier Source: secondary_id
APHP200762
Identifier Type: -
Identifier Source: org_study_id